Skip to main content

Table 4 The effect of charged residue-to-alanine replacement on neutralization capacity of ITM4 plasma, CrossR1 plasma and Mab 4E10

From: Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies

VIRUS COT6.15 MAB 4E10 ITM_01 ITM4_07 CROSSR1
AA MUTATION IC50a IC50b IC50c IC50d
  WT 1,11 603 3544 249
K 667A 0,43 556 >4860 367
N 668A 4,63 117 472 50
L 669A 0,15 929 >4860 528
W 670A 0,93 445 >4860 163
S 671A 0,23 644 >4860 211
W 672A >25 241 4189 115
F 673A >25 70 1177 39
D 674A 4,43 63 516 29
I 675A 0,15 333 >4860 193
T 676A >25 188 2069 61
K 677A 0,38 640 4285 180
W 678A 0,22 801 >4860 391
L 679A 0,49 317 >4860 398
W 680A 4,00 479 >4860 360
  1. AA: amino acids in the 4E10 region of the COT6.15 virus
  2. Alanine-replacements inducing a 3-fold or higher decrease in sensitivity are indicated in grey.
  3. aAntibody concentration (μg/ml) causing 50% reduction of relative light units compared to the virus control.
  4. b Plasma dilution causing 50% reduction of relative light units compared to the virus control.